.jpg?format=webp&width=780)
The study evaluated the effectiveness and safety of insulin glargine/lixisenatide (iGlarLixi) in people with type 2 diabetes according to age. Pooled data from 1316 adults with T2D showed that iGlarLixi was effective in reducing HbA1c and fasting plasma glucose from baseline to week 24, regardless of age. The incidence of adverse events and hypoglycaemic episodes was low in both age subgroups, and iGlarLixi decreased mean body weight in both subgroups. The study concludes that iGlarLixi is effective and well-tolerated in both younger and older people with uncontrolled T2D.
Like
Save
Share